This case highlights the diagnostic and management challenges of refractory multisystem sarcoidosis progressing over a two-year period despite advanced biologic therapy.
🩺 Clinical Context
In interventional pulmonology (IP), the diagnostic workup of undiagnosed pleural effusions remains a cornerstone of our practice. While thoracic ultrasound (TUS) has become the standard of care for guiding pleural biopsies, the integration of advanced imaging modalities—such as ultrasonic elastography—aims to improve the sensitivity of tissue acquisition by identifying areas of increased tissue stiffness (often correlating with malignancy). This correspondence highlights a critical semantic and methodological tension in how we report the success of these interventions: the distinction between “diagnostic yield” (the immediate utility of the procedure) and “diagnostic accuracy” (the long-term confirmation of the diagnosis).
📊 Methodological Strengths & Weaknesses
- Strengths: The original study by Deng et al. is a multicenter, randomized trial, which provides a higher level of evidence than retrospective cohorts. The use of a 12-month follow-up period to establish a “gold standard” for benign disease is a rigorous approach to minimizing false negatives.
- Weaknesses: The primary critique centers on the conflation of diagnostic yield and diagnostic accuracy.
- Misclassification: By defining “diagnostic yield” as (True Positives + True Negatives) / Total Cases, the authors are actually reporting diagnostic accuracy.
- Clinical Utility vs. Retrospective Validation: True diagnostic yield should reflect the procedure’s ability to provide a definitive, actionable diagnosis at the time of the procedure. By including cases that required 12 months of follow-up to confirm a “true negative,” the authors inflate the perceived immediate utility of the elastography-guided biopsy.
- Bias: This methodological choice obscures the “nondiagnostic” rate of the procedure, which is the metric most relevant to an IP physician deciding whether to proceed with a more invasive diagnostic thoracoscopy (VATS) or medical thoracoscopy.
💡 Takeaway for Fellows
- Define Your Metrics: When reading literature on new diagnostic tools (EBUS, navigational bronchoscopy, or pleural biopsy), look closely at how the authors define “yield.” If they include long-term follow-up in their calculation, they are reporting accuracy, not yield.
- The “Actionability” Test: Always ask: “Did this procedure provide a definitive answer that changed management today?” If the answer is “no” because you had to wait for clinical follow-up or repeat imaging, the procedure did not have a high diagnostic yield, regardless of its eventual accuracy.
- Clinical Application: Do not let the “87.83% yield” figure in the Deng et al. study mislead you into thinking that nearly 9 out of 10 patients will have a definitive diagnosis immediately post-procedure. A significant portion of that percentage is derived from retrospective confirmation. When counseling patients, manage expectations regarding the possibility of a non-diagnostic result that necessitates further intervention.
Abstract
Keep reading
N opens the next oneClinicians should note that the presence of targetable mutations in non-small cell lung cancer with malignant pleural disease is not associated with improved survival, based on the findings from this study.
Shape-sensing robotic-assisted bronchoscopy achieved a strict diagnostic yield of 70.2% with a low pneumothorax rate of 3.3%, demonstrating that earlier tissue diagnosis of very small pulmonary nodules is feasible and safe for clinical practice.
CT-guided fiducial placement remains a relevant technique for pre-procedural localization of peripheral lung lesions.
This study introduces ultrasound-guided trans-cannula cryobiopsy of supraclavicular lymph nodes as a novel superficial lymph node approach for tissue acquisition in 10 consecutive patients, though specific numeric success or safety results were not provided in the abstract.
Active infection is not an absolute contraindication to endobronchial valve placement, but positive pressure ventilation significantly increases clinical failure odds with an aOR of 3.00 at P < 0.001.